Drug Name: | Tolbutamide (64-77-7) |
---|---|
PubChem ID: | 5505 |
SMILES: | CCCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)C |
InchiKey: | JLRGJRBPOGGCBT-UHFFFAOYSA-N |
Therapeutic Category: | Hypoglycemic Agents |
Molecular Weight (dalton) | : | 270.354 |
LogP | : | 1.78302 |
Ring Count | : | 1 |
Hydrogen Bond Acceptor Count | : | 3 |
Hydrogen Bond Donor Count | : | 2 |
Total Polar Surface Area | : | 75.27 |
This panel provides information on interacting drugs and their ADRs along with references
Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
---|---|---|---|---|
Phenytoin (57-41-0) | Increase In Blood Glucose | Synergistic | phenytoin-induced hyperglycaemia occurs because the release of insulin from the pancreas is impaired,and antidiabetics competitively inhibit phenytoin hydroxylation by the cytochrome P450 isoenzyme CYP2C9. | The in vitro inhibition of insulin secretion by diphenylhydantoin |
This panel provides drug-protein interaction and their ADRs along with references
Toxicity | Interacting Protein | Mechanism | Reference |
---|---|---|---|
Hypoglycaemia | Cytochrome P450 2C9 (P11712) | Individuals homozygous for Leu359 have markedly diminished metabolic capacities for most CYP2C9 substrates.Consistent with the modulation of enzyme activity by genetic and other factors@ wide interindividual variability occurs in the elimination and/or dosage requirements of prototypic CYP2C9 substrates.Finally@it leads to hypoglycaemia. [ ADR Type 1 ] | Cytochrome P4502C9: an enzyme of major importance in human drug metabolism |
Myelosuppression | sulfonylurea receptors (Q09429) | Myelosuppression [ ADR Type 1 ] | The pharmacogenetics of beta2-adrenergic receptors: relevance to asthma |
This panel provides drug-food interactions and their ADRs along with references
Food | Toxicity | Reference |
---|
This panel provides information on metabolites and their ADRs along with references
Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
---|
This panel provides information on drug category